New York State Teachers Retirement System Has $4.75 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

New York State Teachers Retirement System lifted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 175.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 120,364 shares of the biopharmaceutical company's stock after buying an additional 76,600 shares during the quarter. New York State Teachers Retirement System owned 0.08% of TG Therapeutics worth $4,746,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Arizona State Retirement System increased its holdings in TG Therapeutics by 0.9% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after purchasing an additional 364 shares during the last quarter. Golden State Wealth Management LLC boosted its position in TG Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 433 shares during the period. Summit Investment Advisors Inc. boosted its position in TG Therapeutics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after purchasing an additional 463 shares during the period. NBC Securities Inc. boosted its position in TG Therapeutics by 82,300.0% during the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 823 shares during the period. Finally, Redwood Investments LLC boosted its position in TG Therapeutics by 0.9% during the 4th quarter. Redwood Investments LLC now owns 94,554 shares of the biopharmaceutical company's stock valued at $2,846,000 after purchasing an additional 886 shares during the period. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group assumed coverage on TG Therapeutics in a research report on Thursday. They set a "neutral" rating and a $37.00 price objective for the company. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, TG Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $43.80.

Insider Buying and Selling

In other news, Director Yann Echelard sold 10,000 shares of the stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the transaction, the director directly owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. This represents a 4.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.64% of the stock is currently owned by company insiders.

TG Therapeutics Stock Down 0.7%

NASDAQ TGTX traded down $0.25 on Thursday, reaching $37.67. The stock had a trading volume of 1,335,813 shares, compared to its average volume of 2,889,486. The business has a 50 day moving average price of $36.33 and a 200 day moving average price of $35.21. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03. TG Therapeutics, Inc. has a 1 year low of $16.65 and a 1 year high of $46.48. The company has a market capitalization of $5.98 billion, a price-to-earnings ratio of 156.96 and a beta of 1.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a return on equity of 18.88% and a net margin of 10.13%. The business had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. During the same period in the prior year, the firm posted ($0.07) EPS. TG Therapeutics's revenue for the quarter was up 90.4% on a year-over-year basis. On average, analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.